These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 29357804)
21. Evaluation of Chemically-Cleavable Linkers for Quantitative Mapping of Small Molecule-Cysteinome Reactivity. Rabalski AJ; Bogdan AR; Baranczak A ACS Chem Biol; 2019 Sep; 14(9):1940-1950. PubMed ID: 31430117 [TBL] [Abstract][Full Text] [Related]
22. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates. Frigerio M; Kyle AF Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801 [TBL] [Abstract][Full Text] [Related]
23. Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985. Elgersma RC; Coumans RG; Huijbregts T; Menge WM; Joosten JA; Spijker HJ; de Groot FM; van der Lee MM; Ubink R; van den Dobbelsteen DJ; Egging DF; Dokter WH; Verheijden GF; Lemmens JM; Timmers CM; Beusker PH Mol Pharm; 2015 Jun; 12(6):1813-35. PubMed ID: 25635711 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and ADME characterizations of antibody-drug conjugates. Lin K; Tibbitts J; Shen BQ Methods Mol Biol; 2013; 1045():117-31. PubMed ID: 23913144 [TBL] [Abstract][Full Text] [Related]
25. A comparison of cleavable and noncleavable hydrazinopyridine linkers for the 99mTc labeling of Fab' monoclonal antibody fragments. Bridger GJ; Abrams MJ; Padmanabhan S; Gaul F; Larsen S; Henson GW; Schwartz DA; Longley CB; Burton CA; Ultee ME Bioconjug Chem; 1996; 7(2):255-64. PubMed ID: 8983348 [TBL] [Abstract][Full Text] [Related]
26. A novel concept for cleavable linkers applicable to conjugation chemistry - design, synthesis and characterization. Majumder U; Zhu X; Custar D; Li D; Fang H; McGonigle S; Albone E; Cheng X; Lai W; Siu A; Bresciano K; Hart A; Postema M Chembiochem; 2024 Oct; ():e202400826. PubMed ID: 39424599 [TBL] [Abstract][Full Text] [Related]
28. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics. Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517 [TBL] [Abstract][Full Text] [Related]
29. Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conjugates. Kern JC; Cancilla M; Dooney D; Kwasnjuk K; Zhang R; Beaumont M; Figueroa I; Hsieh S; Liang L; Tomazela D; Zhang J; Brandish PE; Palmieri A; Stivers P; Cheng M; Feng G; Geda P; Shah S; Beck A; Bresson D; Firdos J; Gately D; Knudsen N; Manibusan A; Schultz PG; Sun Y; Garbaccio RM J Am Chem Soc; 2016 Feb; 138(4):1430-45. PubMed ID: 26745435 [TBL] [Abstract][Full Text] [Related]
30. Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells. Salomon PL; Singh R Mol Pharm; 2015 Jun; 12(6):1752-61. PubMed ID: 25738394 [TBL] [Abstract][Full Text] [Related]
31. Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates. Xu S Pharm Res; 2015 Nov; 32(11):3577-83. PubMed ID: 26108878 [TBL] [Abstract][Full Text] [Related]
32. Catabolism of antibody drug conjugates and characterization methods. Shadid M; Bowlin S; Bolleddula J Bioorg Med Chem; 2017 Jun; 25(12):2933-2945. PubMed ID: 28438386 [TBL] [Abstract][Full Text] [Related]
33. A covalent and cleavable antibody-DNA conjugation strategy for sensitive protein detection via immuno-PCR. van Buggenum JA; Gerlach JP; Eising S; Schoonen L; van Eijl RA; Tanis SE; Hogeweg M; Hubner NC; van Hest JC; Bonger KM; Mulder KW Sci Rep; 2016 Mar; 6():22675. PubMed ID: 26947912 [TBL] [Abstract][Full Text] [Related]
34. A new anti-human Fc method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in serum from pre-clinical species. Excoffier M; Janin-Bussat MC; Beau-Larvor C; Troncy L; Corvaia N; Beck A; Klinguer-Hamour C J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():149-154. PubMed ID: 27267073 [TBL] [Abstract][Full Text] [Related]
36. Chelate radiochemistry: cleavable linkers lead to altered levels of radioactivity in the liver. Meares CF; McCall MJ; Deshpande SV; DeNardo SJ; Goodwin DA Int J Cancer Suppl; 1988; 2():99-102. PubMed ID: 3162452 [TBL] [Abstract][Full Text] [Related]
37. Antibody-cytotoxic agent conjugates: preparation and characterization. Singh R; Erickson HK Methods Mol Biol; 2009; 525():445-67, xiv. PubMed ID: 19252846 [TBL] [Abstract][Full Text] [Related]
38. Contribution of linker stability to the activities of anticancer immunoconjugates. Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937 [TBL] [Abstract][Full Text] [Related]
39. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates. Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844 [TBL] [Abstract][Full Text] [Related]